Literature DB >> 10466051

Successful management of post-esophagectomy chylothorax/chyloperitoneum by etilefrine.

P Guillem1, V Billeret, M L Houcke, J P Triboulet.   

Abstract

Post-operative chylothorax and chyloperitoneum resulting from a thoracic duct injury are possible complications of esophagectomy for carcinoma. Management of such conditions includes conservative methods (pleural drainage, chyle flow reduction and supportive nutrition) and surgery. Etilefrine, a sympathomimetic drug used in the management of postural hypotension, also causes smooth muscle contraction of the thoracic duct. We successfully treated three patients with post-esophagectomy chylothorax and chyloperitoneum using intravenous etilefrine. Etilefrine infusion allowed chyle flow resolution in a few days without any side-effects. As result of this experience, we believe that etilefrine deserves to be considered as an alternative therapy in the management of post-esophagectomy chylothorax/chyloperitoneum.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466051     DOI: 10.1046/j.1442-2050.1999.00021.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  14 in total

1.  Does fibrin glue reduce lymph leakage (pleural effusion) after extended esophagectomy? Prospective randomized clinical trial.

Authors:  Mitsuo Tachibana; Shoichi Kinugasa; Hiroshi Yoshimura; Dipok Kumar Dhar; Shuhei Ueda; Toshiyuki Fujii; Hitoshi Kohno; Naofumi Nagasue
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

Review 2.  Chylothorax complicating thoracic surgery: conservative or early surgical management?

Authors:  Panagiotis Misthos; Meletios A Kanakis; Achilleas G Lioulias
Journal:  Updates Surg       Date:  2012-01-13

3.  Chylothorax after blunt trauma.

Authors:  Eric Seitelman; Jason J Arellano; Kazuaki Takabe; Leonard Barrett; Glenn Faust; L D George Angus
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

Review 4.  Thoracic duct injury following esophagectomy in carcinoma of the esophagus: ligation by the abdominal approach.

Authors:  Pramod Kumar Mishra; Sundeep Singh Saluja; Dinesh Ramaswamy; Satinderpal Singh Bains; Parvez David Haque
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

5.  Postoperative chyle leak after major pancreatic resections in patients who receive enteral feed: risk factors and management options.

Authors:  Mohammed Abu Hilal; David M Layfield; Francesco Di Fabio; Irantzu Arregui-Fresneda; Ioanna G Panagiotopoulou; Thomas H Armstrong; Neil W Pearce; Colin D Johnson
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

6.  Ultrasound-guided intranodal lipiodol lymphangiography from the groin is useful for assessment and treatment of post-esophagectomy chylothorax in three cases.

Authors:  Jiajia Liu; Yusuke Sato; Satoru Motoyama; Koichi Ishiyama; Kentaro Yamada; Masayoshi Yamamoto; Akiyuki Wakita; Yuta Kawakita; Kazuhiro Imai; Hajime Saito; Manabu Hashimoto; Yoshihiro Minamiya
Journal:  Int J Surg Case Rep       Date:  2016-11-03

7.  Effectiveness of etilefrine regimen for chylothorax after esophagectomy with thoracic duct resection.

Authors:  Yu Ohkura; Masaki Ueno; Toshiro Iizuka; Harushi Udagawa
Journal:  Esophagus       Date:  2017-09-14       Impact factor: 4.230

Review 8.  Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment.

Authors:  Richa Bhardwaj; Haleh Vaziri; Arun Gautam; Enrique Ballesteros; David Karimeddini; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2017-12-04

Review 9.  Chylous Ascites: Evaluation and Management.

Authors:  Said A Al-Busafi; Peter Ghali; Marc Deschênes; Philip Wong
Journal:  ISRN Hepatol       Date:  2014-02-03

10.  New Combined Medical Treatment With Etilefrine and Octreotide for Chylothorax After Esophagectomy: A Case Report and Review of the Literature.

Authors:  Yu Ohkura; Masaki Ueno; Toshiro Iizuka; Shusuke Haruta; Tsuyoshi Tanaka; Harushi Udagawa
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.